好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Long-term outcomes of late deep brain stimulation in DYT1 dystonia
Movement Disorders
P4 - Poster Session 4 (5:30 PM-6:30 PM)
10-002

To determine whether primary dystonia patients with DYT1 mutation benefit from deep brain stimulation (DBS) surgery even with 10 or more years between onset of symptoms and surgery.

Several factors have been postulated to be associated with response to DBS, including disease duration prior to surgery. 

We performed a retrospective review of dystonia patients with GAG deletion in TOR1A, with greater than 10-year disease duration prior to DBS.  Preliminary analysis identified nine individuals with information regarding pre and post-operative Burke-Fahn Marsden Dystonia Rating Scale (BFMDRS) motor score and medication.  Six subjects were female.  Average age at onset was 9.9 ± 3.0(7-17) years.  Average age at DBS surgery was 41.3 ± 14.3(24-59) years; average duration between dystonia onset and surgery was 31.4 ± 14.6(14-52) years.  All cases targeted bilateral internal pallidum (GPi-DBS).

Average pre-operative BFMMS was 35.9 ± 17.6(8-70.5).  Average post-operative BFMMS was 16.1 ± 13.5(1.5-40.5).  Average decrease was 19.8 ± 15.4(5-52.5), reflecting an average BFMMS percentage improvement of 59.0 ± 29.9(11.0-87.9).   Post-operative BFMMS was performed at an average of 12 months from surgery.  While BFMMS was not necessarily performed at date of last follow-up, sustained benefit was documented in eight cases.  Mean length of follow-up was 4.1 ± 3(1-10) years.  All cases had post-operative medication reduction; two stopped all dystonia medications.  None had lead fracture or hardware malfunction; one had superficial infection. 

Our results in this relatively large cohort of DYT1 cases to undergo surgery in adulthood suggest that late presentation to DBS is still associated with significant improvement in motoric scores and medication reduction.  Thus, even for DYT1 patients with late diagnosis or other rationale for DBS delay, DBS may still be an effective treatment modality.  Further analysis of longer term outcomes is underway.  Comparison with cases that underwent surgery within ten years of disease duration is also underway.

Authors/Disclosures
Hwai Y. Ooi, MD (NYP- Weill Cornell)
PRESENTER
Dr. Ooi has nothing to disclose.
Joan Miravite, DNP, RN, FNP-BC, FAAN, FAANP, DAAN (Mount Sinai West) Dr. Miravite has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Miravite has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. Dr. Miravite has a non-compensated relationship as a Board Member with Association of Movement Disorder Advanced Practice Providers that is relevant to AAN interests or activities.
Deborah Raymond (Beth Isreal Medical Center) The institution of Ms. Raymond has received research support from NIH.
No disclosure on file
Harini Sarva, MD, FAAN (Weill Cornell Medical Center) Dr. Sarva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Sarva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuroderm. Dr. Sarva has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Insightec. The institution of Dr. Sarva has received research support from Insightec. The institution of Dr. Sarva has received research support from NeuroNext. The institution of Dr. Sarva has received research support from Neuroderm. The institution of Dr. Sarva has received research support from Sun Pharma. The institution of Dr. Sarva has received research support from Prevail. The institution of Dr. Sarva has received research support from Bluerock Therapeutics. The institution of Dr. Sarva has received research support from Biogen. The institution of Dr. Sarva has received research support from Roche. The institution of Dr. Sarva has received research support from National Institute of Aging. The institution of Dr. Sarva has received research support from Michael J Fox Foundation. The institution of Dr. Sarva has received research support from Novo Nordisk. The institution of Dr. Sarva has received research support from Bukwang. The institution of Dr. Sarva has received research support from Bial. The institution of Dr. Sarva has received research support from Cerevance. The institution of Dr. Sarva has received research support from UCB. The institution of Dr. Sarva has received research support from MeiraGTX. The institution of Dr. Sarva has received research support from Biohaven. The institution of Dr. Sarva has received research support from Vima.
Fedor Panov Fedor Panov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for neuropace. Fedor Panov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for zimmer biomet.
Michele Tagliati, MD, FAAN (Cedars-Sinai Medical Center) Dr. Tagliati has received publishing royalties from a publication relating to health care.
No disclosure on file
Brian Kopell No disclosure on file
Susan B. Bressman, MD, FAAN (Mount Sinai Health System) The institution of Dr. Bressman has received research support from Michael J Fox Foundation . The institution of Dr. Bressman has received research support from NIH .
Rachel J. Saunders-Pullman, MD (Mount Sinai Beth Israel, Neurology, Downtown Union Square) The institution of Dr. Saunders-Pullman has received research support from NIH, Bigglesworth Family Foundation, Empire Clinical Research Investigatory Program.